CD4 News and Research

RSS

Do kidney transplant recipients need a third booster dose of mRNA COVID-19 vaccine?

A team of researchers in France have observed that the “standard” 2 dose regimen for mRNA COVID-19 vaccines could provide adequate protection to only a few KTRs. It has also been shown in multiple studies that a considerable population of vaccinated KTRs were easily infected with SARS-CoV-2.

1 Sep 2021

Can barrier gestures be relaxed without causing a COVID-19 resurgence in France?

A new study focused on determining the magnitudes of a barrier gesture relaxation in France. Read more here.

1 Sep 2021

Durability of cellular immune memory to SARS-CoV-2 after mRNA vaccination

A recent study, available on the bioRxiv* preprint server, investigated the durability of cellular immune memory after mRNA vaccination against SARS-CoV-2 and whether booster jabs affect the durability of different immune response components. The study included testing for antibodies and cellular immune responses in covid patients and recovered individuals.

31 Aug 2021

The impact of mild SARS-CoV-2 infection on maternal-fetal immunity

Recently, a new study published on the pre-print server bioRxiv* examined the effect that maternal asymptomatic COVID-19 had on decidual and peripheral immune cells during the later stage of pregnancy.

30 Aug 2021

Next-gen COVID vaccine to make persistent neutralizing antibodies

Presently, there is a need to develop improved versions of COVID-19 vaccines that are effective against the SARS-CoV-2 variants of concern (VOC) and can confer long-term protection. Considering the need of the hour, scientists from the University of Sydney in Australia have generated a new COVID-19 vaccine CoVac-II and evaluated its effect against COVID-19 strains. The findings from this study are published on the bioRxiv* preprint server while awaiting peer review.

30 Aug 2021

MS patients on anti-CD20 therapy have robust T cell responses to SARS-CoV-2 vaccination

Scientists have observed that MS patients exhibit a robust T cell response despite a reduced humoral response to COVID-19 vaccines. Read more here.

27 Aug 2021

Could soluble CD24 offer some hope against severe COVID-19?

A recent randomized phase III trial conducted by researchers at the Ohio State University, Columbus, OH, US, evaluated the impact of CD24Fc in severe COVID-19 patients and showed promising clinical efficacy. This study is available as a preprint on the medRxiv* server.

26 Aug 2021

Analysis of antibody titer decay following vaccination or SARS-CoV-2 infection

A new study focused on the decrease in antibody titers following two doses of BNT162b2 vaccine or SARS-CoV-2 natural infection in Israel.

25 Aug 2021

Unconventional T cell and inflammation levels in COVID-19 during pregnancy

A new study published on the medRxiv* preprint server has focused on investigating SARS-CoV-2 immune responses in pregnant women

25 Aug 2021

Glycyrrhizic acid as a drug candidate for COVID-19

A new study presents the benefits of licorice, an age-old herbal remedy, to treat COVID-19 at all stages.

24 Aug 2021

New $14.5 million NIH grant to support research on HIV treatment and care in Central Africa

Researchers at Albert Einstein College of Medicine and the City University of New York Graduate School of Public Health and Health Policy have been awarded a five-year, $14.5 million grant from the National Institutes of Health to continue leading and expand their research on HIV treatment and care in five Central African nations.

24 Aug 2021

COVID booster shots might be needed in subgroup of HIV-positive individuals

The coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into a global pandemic destroying lives and economies. COVID-19 is not curable, so vaccines are the only safeguard during this pandemic.

23 Aug 2021

Durable highly protective T cell response to AAV-spike vaccine against COVID-19 pneumonia in mice

New research, available as a preprint on the bioRxiv* server, has focused on the role played by T cell immunity, particularly CD8+ cytotoxic T cells, on preventing lethal infection with SARS-CoV-2 in mice infused with peptide-loaded antigen-presenting dendritic cells (DCs).

19 Aug 2021

In Southeast Asia, robust immunity found up to 9 months after SARS-CoV-2 infection

Now, a new study posted to the bioRxiv* preprint server focuses on functional immune memory to SARS-CoV-2, up to nine months in a Southeast Asian cohort, in the absence of re-infection.

16 Aug 2021

Penn researchers reveal complex details of T-cell responses to mRNA COVID-19 vaccines

Messenger-RNA (mRNA) vaccines against the coronavirus that causes COVID-19 provoke a swift and strong response by the immune system's T cells - the heavy armor of the immune system - according to a study from researchers in the Perelman School of Medicine at the University of Pennsylvania.

16 Aug 2021

Risk factors for hospitalization among HIV patients infected with SARS-CoV-2

The hospitalization of PWH with COVID-19 is related to host factors such as older age and co-morbidities, rather than due to traditional metrics of HIV.

11 Aug 2021

COVID-19 vaccine likely protects people living with HIV, study shows

A Johns Hopkins Medicine research team has shown that people living with the human immunodeficiency virus (HIV) are likely to be protected against SARS-CoV-2, the virus that causes COVID-19, if they are fully vaccinated.

11 Aug 2021

Long COVID may be due to persistent immune disturbances

A new study discusses abnormalities in the immune response following COVID-19 in samples collected from patients who have recovered from COVID-19.

8 Aug 2021

Vaccinia-based COVID-19 vaccines confer immunity in hamster model

In a paper recently uploaded to the preprint server bioRxiv* by Kulkarni et al. (August 3, 2021), the potential of vaccinia virus-based vaccines expressing the full-length SARS-CoV-2 spike protein is examined in mice and Syrian hamsters. The findings report that the vaccine generates high titers of neutralizing antibodies with good activity towards SARS-CoV-2 variants of concern.

5 Aug 2021

Heterologous prime-boost vaccination induces robust mucosal and systemic immunity against SARS-CoV-2

Scientists from Germany and Italy recently demonstrated the benefits of intramuscular/intranasal heterologous prime-boost vaccination regimen against coronavirus disease 2019 (COVID-19).

4 Aug 2021